

Curriculum vitae

Version date: 2021

Name: Sanjay Kulkarni, MD MHCM

School: Yale University School of Medicine

Education:

1986-1990 Bachelor of Science (BS)
Majors: Biochemistry and Molecular Biology
University of Wisconsin-Madison
Madison, WI

1990-1995 Medical Doctorate (MD)
Medical College of Wisconsin
Milwaukee, WI

2002-2004 Clinical Research Training Program
Department of Health Studies
Pritzker School of Medicine
University of Chicago
Chicago, IL

2014-2015 Global Clinical Research Scholars
Harvard Medical School
Boston, MA

2016-2018 Master's in Healthcare Management (MHCM)
Harvard School of Public Health
Boston, MA

Career/Academic Appointments:

1995-2002 General Surgery Resident
Department of Surgery
University of Chicago Hospitals
Chicago, IL

2001-2002 Administrative Chief Surgical Resident
Department of Surgery
University of Chicago Hospitals

Chicago, IL

2002-2004 Transplant Surgery Fellow
Department of Surgery, Section of Transplantation
University of Chicago Hospitals
Chicago, IL

2002-2004 Clinical Instructor
Department of Surgery, Section of Transplantation
University of Chicago Hospitals
Chicago, IL

2004-2011 Assistant Professor of Surgery
Yale University School of Medicine
New Haven, CT

07/2011-present Associate Professor of Surgery & Medicine
Yale University School of Medicine
New Haven, CT

Administrative Positions:

2007-ongoing Surgical Director, Kidney Transplantation, Yale-New Haven
Hospital, New Haven, CT

2014-2021 Director, Transplant Research, Yale School of Medicine,
New Haven, CT

2016-ongoing Medical Director, Center for Living Organ Donors, Yale-New
Haven Hospital, New Haven, CT

2019-ongoing Medical Director, New England Donor Services, Waltham,
MA

2021-ongoing Physician Executive Director, Clinical Continuity &
Integration, Yale-New Haven Hospital, New Haven, CT

Board Certification:

1997 National Board of Medical Examiners

2003-2012 American Board of Surgery (#48019)

2012-2022 American Board of Surgery, recertification

Professional Honors & Recognition:

2007-ongoing Fellow of the American College of Surgeons
2008 Gift of Life, Record Achievement Award, Yale-New Haven Hospital
2015-2021 Castle Connolly Best Surgeons in Northeast
2019 National Kidney Foundation Achievement Award

Grant/Clinical Trials History:

Current Grants:

Agency: NIH/KUPD study section
ID#: 11 DK132473-01
Title: Pre-transplant Resuscitation of Marginal Kidneys on Normothermic Perfusion (PROMISE): A Pilot Clinical Trial
PI: Sanjay Kulkarni, MD MHCM (Co-PI) and Gregory Tietjen PhD (Co-PI)
Percent effort: 5%
Total costs: 1,300,000 (Indirect costs: \$877,500)
Project period: (pending study section review October 14-15, 2021)

Past Grants:

Agency: Greenwall Foundation
ID# HIC 1403013661
Title: Balancing Non-Maleficence and Autonomy: Establishing Ethical Risk Thresholds for Living Kidney Donors
Role: Principal Investigator
Percent effort: 5%
Total costs: \$138,300 (Indirect costs: \$41,000)
Total Indirect Costs: \$41,000
Project dates: 2015-2018

Agency: Alexion Pharmaceuticals (investigator-initiated)
ID#: HIC 1407014309
Title: Burden of Illness in Highly Sensitized ESRD Patients & Patients Who Experience Acute Antibody-Mediated Rejection
Role: Principal Investigator
Percent effort: 10%

Total Direct Costs: \$165,569 (Indirect costs: \$31,044)
Total Indirect Costs: \$31,044
Project period: 2015-2018

Agency: Transplantation Immunology Research Network (TIRN)
ID#: n/a
Title: Financial burdens and coping mechanisms of living kidney donors
Role: Faculty advisor (awardee Sienna Li)
Effort: n/a
Total costs: \$2000
Project dates: 2016

Agency: Transplantation Immunology Research Network (TIRN)
ID#: n/a
Title: Opting Out and Offers of 'Alibis' for Potential Living Kidney Donors at US Transplant Centers
Role: Faculty advisor (awardee Renata Iskandar)
Effort: n/a
Total costs: \$2000
Project dates: 2017

Past Clinical Trials:

Agency: Wyeth Pharmaceuticals
ID#: NCT00038948
Title: Sirolimus 316- A Randomized, Open-Label, Comparative Evaluation of Conversion from Calcineurin Inhibitors to Sirolimus Versus Continued Use of Calcineurin Inhibitors in Renal Allograft Recipients
Role: Principal Investigator (Yale Site)
Effort: 2%
Total costs: \$162,832 (Indirect costs: \$48,850)
Project dates: 2002-2009

Agency: Wyeth Pharmaceuticals
ID#: NCT00266123
Title: ORION-A Randomized Open-Label Study to Compare the Safety and Efficacy of Two Different Sirolimus Regimens with a Tacrolimus + Mycophenolate Mofetil Regimen in De Novo Renal Allograft Recipients
Role: Principal Investigator (Yale Site)
Effort: 2%
Total costs: \$152,620 (Indirect costs: \$35,220)

Project dates: 2005-2008

Agency: Pfizer Pharmaceuticals
ID#: NCT00483756
Title: CP-690,550; A Phase 2 Randomized, Multicenter, Active Comparator-Controlled Trial to Evaluate the Safety and Efficacy of Coadministration of CP-690,550 and Mycophenolate Mofetil/Mycophenolate Sodium in De Novo Kidney Allograft Recipients
Role: Principal Investigator (Yale Site)
Effort: 2%
Total Direct Costs: \$102,456 (Indirect costs: \$23,644)
Dates: 2007-2010

Agency: Pfizer Pharmaceuticals
ID#: NCT00658359
Title: CP-690,550 Extension; A Phase 2, Multicenter, Open-Label, Active Comparator-Controlled, Extension Trial to Evaluate the Long-Term Safety and Efficacy of CP-690,550 in Renal Allograft Recipients
Role: Principal Investigator (Yale Site)
Effort: 2%
Total costs: \$67,771 (Indirect costs: \$20,331)
Project dates: 2008-2012

Agency: Life Cycle Pharmaceuticals
ID#: NCT00817206
Title: LCP-Tacro: A Phase 3, Open-Label, Multicenter, Prospective, Randomized Study to Determine the Efficacy and Safety of Conversion of Prograf Capsules Twice Daily to LCP-Tacro Tablets Once Daily for the Prevention of Acute Allograft Rejection in Stable Kidney Transplant Patients
Role: Principal Investigator (Yale Site)
Effort: 2%
Total Direct Costs: \$171,093 (Indirect costs: \$39,483)
Project dates: 2009 to 2012

Agency: Veloxis Pharmaceuticals
ID#: NCT01187953
Title: A Phase 3, Double-Blind, Double-Dummy, Multi-Center, Prospective, Randomized Study of the Efficacy and Safety of LCP Tacro Tablets, Once Daily, Compared to Prograf Capsules, Twice Daily, in Combination with Mycophenolate Mofetil for the

prevention of Acute Allograft Rejection in De Novo Adult Kidney Transplant Recipients
Role: Principal Investigator (Yale Site)
Effort: 1%
Total costs: \$168,901 (Indirect costs: \$38,977)
Project dates: 2010-2015

Agency: Alexion Pharmaceuticals (**investigator-initiated**)
ID#: NCT01327573
Title: Inhibition of Complement in Chronic Allograft Injury & its Effect on Circulating Endothelial Cells
Role: Principal Investigator & IND holder (#109,360)
Effort: %15
Total Direct Costs: \$995,107 (Indirect costs: \$229,640)
Project dates: 2011-2016

Agency: NIH/NIAID
ID#: U01AI063594
Title: Randomized Controlled Trial of Infliximab Induction Therapy for Deceased Donor Kidney Transplant Recipients
Role: Co-Investigator
Effort: 5%
Total Direct Costs: \$131,487 (Indirect costs: \$43,252)
Project dates: 2014-2019

Agency: Bristol-Meyers Squibb
ID#: NCT01820572
Title: Evaluation of Benefits and Risks in Maintenance Renal Transplant Recipient Following conversion to Belatacept-Based Immunosuppression IM103-11
Role: Principal Investigator
Effort: 1%
Total Direct Costs: \$212,006 (Indirect costs: \$48,924)
Project dates: 2014-2018

Agency: Surgique, Inc. (**investigator-initiated**)
ID#: HIC 1405013985
Title: Randomized Controlled Trial of Reducing Operative & Post-Operative Morbidity in Living Kidney Donors Utilizing Low Pressure, Limited Variability Pneumoperitoneum
Role: Principal Investigator
Effort: 10%
Total Direct Costs: \$98,000 (Indirect costs: \$29,400)

Project dates: 2014-2017

Agency: Alexion Pharmaceuticals
ID#: NCT01919346
Title: Eculizumab for Prevention of Delayed Graft Function in Deceased Donor Kidney Transplantation
Role: Principal Investigator (Yale Site)
Overall Principal Investigator (Peter Heeger MD, Mt. Sinai Medical School)

Effort: 2.5%

Total costs: \$63,849 (Indirect costs: \$14,734)

Project dates: 2014-2017

Agency: Alexion Pharmaceuticals (**investigator-initiated**)
ID#: ETS208342
Title: A Matched Intervention Pilot Trial of Eculizumab Therapy to Reduce Preservation Injury in Human Macrosteatotic Liver Transplantation
Role: Principal Investigator & IND holder (#136,654)
Percent effort: n/a
Total costs: \$250,000 drug support
Project period: 01/2019-04/2021

Invited Speaking Engagements, Presentations & Workshops Not Affiliated with Yale:

International/National:

- 2010 "Complement Inhibition in Chronic Antibody Mediated Rejection and its Effect on Circulating Endothelial Cells", University of Cambridge, Cambridge, UK.
- 2010 "Center Coordinated, Pre-transplant Evaluation Eliminates Barriers to Kidney Transplantation and Establishes Parity Across Socio-Economic Groups", Ochsner Clinic, New Orleans, LA.
- 2011 "Complication Management Following Kidney Transplantation" *Sanatorio Allende Hospital, Cordoba, Argentina.*
- 2012 "A QI Initiative and Improves Access to Kidney Transplantation" *Transplant Grand Rounds, University of Cincinnati, Cincinnati, OH.*
- 2014 "Protecting Living Kidney Donors: Empirical and Normative Advances". Living kidney donor risks and benefits: A review of evaluation consent

forms. Invited Panel. *American Society for Bioethics and the Humanities 2014 Annual Meeting* San Diego, CA.

- 2015 “Donor expectations: donor reality vs medical reality. Developing Local Donor Communities” *Donor Advocate Symposium*. Baylor Transplant Center, Dallas, TX.
- 2017 “Long-term Support for Living Donors: Developing Local Donor Communities” *Donor Advocate Symposium*. Baylor Transplant Center, Dallas, TX.
- 2017 “Argon beam coagulation: the liver transplant challenge”, *ConMed Annual Meeting*, Orlando, FL.
- 2018 “I Gave. You Got. Now What? Long-term Support for the Living Donor” *9th International Conference: Living Donor Abdominal Organ Transplantation State of the Art*, Matera, Italy.
- 2018 “Framing Decisions in Transplantation *Room for Libertarian Paternalism?*” *University of Cambridge*, Cambridge, UK.
- 2018 “Defining Success in Transplantation: Problems with Societal Measurement” *The Split Rock Group*, Dallas, TX.
- 2019 “Evolving Transplant Biases to Patient-Centered Decision-Making Utilizing Choice Architecture” *The International Symposium on Clinical Neuroscience*, Orlando, FL.
- 2020 “Organ supply vs. graft failure: towards an integrated service model for organ transplant management”, *CSL Behring*, King of Prussia, PA.
- 2021 “Liver transplant ultrasound: surgical perspectives”, *American Institute of Ultrasound in Medicine*, Virtual.

Regional:

- 2010 “Utilization of Marginal Organs for Transplantation” *New England Organ Bank*, Wooster, MA
- 2011 “Pancreas Transplantation: Balancing glycemic control with surgical morbidity”, Medical Grand Rounds, *Hartford Hospital*, Hartford, CT.
- 2011 “Organ procurement: liver”, Scientific Advisory Board, *Alexion Pharmaceuticals*, Cambridge, MA.

2016 “Eculizumab for chronic antibody-mediated injury in kidney transplant recipients. *Alexion Pharmaceuticals*, New Haven, CT.

Peer-Reviewed Presentation & Symposia Given at Meetings Not Affiliate with Yale :

National/International (Oral presentations):

1. Center Coordinated, Pre-Transplant Evaluation Eliminates Barriers to Kidney Transplantation & Establishes Parity Across Socio-economic Groups. The International Congress of the Transplantation Society. August 17, 2010. Vancouver, BCI.
2. Workshop on essential elements of donor and recipient evaluations. World Transplant Congress. June 2013. Seattle, WA.
3. Opting Out: Confidentiality & Alibis for Living Kidney Donor. American Society for Bioethics and the Humanities. Atlanta, GA. October 2013.
4. Living Kidney Donor Consent: Compliance with CMS & OPTN Requirements. Concurrent Session 43: Regulation & Donation. American Transplant Congress. Seattle, WA. May 2013.
5. Opting Out: Confidentiality & Alibis for Living Kidney Donors. American Transplant Congress. Seattle, WA. May 2013.
6. Eculizumab Therapy for Chronic Antibody-Mediated Rejection: A Preliminary Assessment. American Transplant Congress. Seattle, WA. May 2013.
7. Eculizumab Therapy for Chronic Antibody-Mediated Rejection World Transplant Congress, June 2014. San Francisco, CA.
8. The Stanford Integrated Psychosocial Assessment for Transplantation, Healthcare Utilization, and Adverse Medical Events for 3 Years Post-Kidney Transplantation. American Psychosomatic Medicine 2014 Annual Meeting. Ft. Lauderdale. FL. 12-15 November 2014.
9. The Stanford Integrated Psychosocial Assessment for Transplantation, Healthcare Utilization, and Adverse Medical Events for 3 Years Post-Kidney Transplantation. European Association of Psychosomatic Medicine 2015. Nuremberg, Germany. 2-4 July 2015.

10. "I Can't Become Homeless in Order to Help My Daughter": Reasons for and the Psychosocial Impact of Opting Out of Living Kidney Donation. American Society for Bioethics & the Humanities. 22-25 October 2015. Houston, TX.
11. Shared Decision-making During the Living Kidney Donor Evaluation Process: Results of a Prospective Qualitative Study. American Society for Bioethics & the Humanities. 22-25 October 2015. Houston, TX.
12. A Donor-Centered Approach to Risk Assessment: Normative Considerations for and Against Shared Decision Making in Living Kidney Donor Evaluation. American Society for Bioethics & the Humanities. 22-25 October 2015. Houston, TX.
13. Implementation of a Donor-Centered Approach to Living Kidney Donor Evaluation: Challenges and Opportunities for Transplant Centers. American Society for Bioethics & the Humanities. 22-25 October 2015. Houston, TX.
14. Living Kidney Donor Risk Preferences: Quantifying Risk Acceptance Using a Novel Decision-making Aid. American Society for Bioethics & the Humanities. 22-25 October 2015, Houston, TX.
15. Living Kidney Donor Preferences: A Novel Use of a Visual Instrument to Quantify ESRD Risk Acceptance. American Surgical Congress. 2-4 February 2016. Jacksonville, FL.
16. Low-Pressure Laparoscopic Donor Nephrectomy is Associated with Improved Donor and Recipient Outcomes. American Surgical Congress. 2-4 February 2016. Jacksonville, FL.
17. Balancing Non-Maleficence and Autonomy: A Donor-Centered Approach to Risk Assessment. European Society of Transplantation (ESOT)/Ethical, Legal and Psychosocial Aspects of Transplantation (ELPAT). 22-25 April 2016. Rome, Italy.
18. Living Kidney Donor Preferences: A Novel Use of a Visual Instrument to Quantify ESRD Risk Acceptance. European Society of Transplantation (ESOT)/Ethical, Legal and Psychosocial Aspects of Transplantation (ELPAT). 22-25 April 2016. Rome, Italy.
19. Financial Burdens and Coping Mechanisms of Living Kidney Donors. American Transplant Congress. 11-15 June 2016. Boston, MA.
20. Who Should Decide? Potential Living Kidney Donor Preferences for Making Decisions About Risk. American Transplant Congress. 11-15 June 2016. Boston, MA.

21. How Potential Living Kidney Donors (LKDS) View ESRD Risk: A Multi-Center Study. European Society of Transplantation. 24-28 September 2017. Barcelona, Spain.
22. KAS Implementation Reduces Racial Disparities in Access to Transplant in the US: A Multi-State Modelling Approach Using Time-Varying PRA States and Activity Status. European Society of Transplantation. 24-28 September 2017. Barcelona, Spain.
23. How Potential Living Kidney Donors (LKDs) View ESRD Risk: A Longitudinal, Multi-Center Study. Clinical Congress 2018 American College of Surgeons October 21-24, 2018. Boston MA.
24. Building Local Communities of Prior Living Donors and Creating a Social Architecture to Improve Rates of Living Kidney Donation. Clinical Congress 2018 American College of Surgeons October 21-24, 2018. Boston MA.
25. Ongoing Disparities in Access to Kidney Transplantation in the Post-KAS Era. Clinical Congress 2018 American College of Surgeons, October 21-24, 2018, Boston MA.
26. Improving Immunosuppression Drug Accuracy Through Pharmacy-Directed Medication Reconciliation. European Society of Transplantation Congress, September 15-18, 2019. Copenhagen, Denmark.
27. Ineligible: Attitudes and Follow-up of Individuals Ruled Out of Living Kidney Donation. European Society of Transplantation Congress, September 15-18. 2019, Copenhagen, Denmark.
28. Inactive Status Change is an Independent Predictor of Waitlist Mortality and Disproportionately Impacts Patients in Donor Service Areas with a Higher MMaT. International Liver Transplant Society Annual Congress. May 6-9, 2020. Istanbul, Turkey.
29. Inactive Status Changes Disproportionately Impacts the Probability of Obtaining a Deceased Donor Liver Transplant in Donation Service Areas with Higher MMaT. American Transplant Congress. May 30-June 3, 2020.

National/International (Poster presentations)

1. Informed consent for living liver donation: compliance with CMS & OPTN requirements and alibi offers. Joint International Congress of ILTS, ELITA & LICAGE. London, United Kingdom. 4-7 June 2014.
2. The Stanford Integrated Psychosocial Assessment for Transplantation, Healthcare Utilization, and Adverse Medical Events for 3 Years Post-Kidney Transplantation. World Transplant Congress. San Francisco CA. 26-31 July 2014.
3. Burden of Disease in Kidney Transplant Recipients with Low Immunologic Risk Antibody-Mediated Rejection. American Transplant Congress. 2-6, May 2015.
4. Living Kidney Donor Risk Preferences: Quantifying Risk Acceptance Using a Novel Decision-Making Aid. American Society of Transplant Surgeons Winter Symposium. Miami, FL. 14-17 January 2016. **Awarded Poster of Distinction.**
5. Living Kidney Donor Preferences: A Novel Use of a Visual Instrument to Quantify ESRD Risk Acceptance. American Transplant Congress. 11-15, June 2016.
6. Opting Out: A Pilot Study Assessing the Reasons for and the Psychosocial Impact of Withdrawing from Living Kidney Donor Evaluation. European Society of Transplantation (ESOT)/Ethical, Legal and Psychosocial Aspects of Transplantation (ELPAT). 22-25 April 2016, Rome, Italy.
7. Attitudes Toward Living Kidney Transplantation Among Potential Transplant Recipients. *American Transplant Congress*. 11-15, June 2016.
8. Low-Pressure Pneumoperitoneum in Living Kidney Donors: A Randomized-Controlled Trial. American Transplant Congress. 11-15, June 2016.
9. Eculizumab Therapy for Chronic Antibody-Mediated Rejection in Kidney Transplant Recipients: A Randomized-Controlled Trial. American Transplant Congress. 11-15, June 2016. **Awarded Poster of Distinction.**
10. A Novel KPD Mechanism to Increase Transplants When Some Candidates Have Multiple Willing Donors. American Transplant Congress. 29 April – 3 May 2017.
11. How Potential Living Kidney Donors (LKDS) View ESRD Risk: A Multi-Center Study. American Transplant Congress. 29 April – 3 May 2017.
12. A Multistate Model of Time-Varying PRA States and its Impact on Kidney Transplant: A Focus on KAS Implementation. American Transplant Congress. 29 April – 3 May 2017.

13. Opting Out and Offers of 'Alibis' for Potential Living Kidney Donors at US Transplant Centers. American Transplant Congress. 2 June-6 June 2018. **Awarded Poster of Distinction.**
14. Ineligible: Attitudes and Follow-up of Individuals Ruled Out of Living Kidney Donation. American Society of Transplant Surgeons Winter Symposium. 10 January-13 January 2019.
15. Improving Immunosuppression Drug Accuracy through Pharmacy-Directed Medication Reconciliation. American Society of Transplant Surgeons Winter Symposium. 10 January-13 January 2019.
16. Waitlist Management is a Primary Driver of Observed Regional Differences in US Liver Transplant Distribution. European Society of Transplantation Congress, September 15-18, 2019, Copenhagen, Denmark.
17. The Link Between Waitlist Mortality and Access to Transplant, an Imaginative Reality. International Liver Transplant Society Annual Congress. May 6-9, 2020. Istanbul, Turkey.
18. Waitlist Mortality and Transplant Probability for Inactively Listed Liver Patients Depends on Donor Service Area's MMaT. International Liver Transplant Society Annual Congress. May 6-9, 2020. Istanbul, Turkey.
19. Higher Probability of Living Donor Liver Transplantation is Associated with DSA's With a Higher MMaT. American Transplant Congress. May 30-June 3, 2020.
20. Patients in Donor Service Areas with Higher MMaT have a Lower Probability of Liver Transplant Waitlist Activation. American Transplant Congress. May 30-June 3, 2020.

Professional Service:

Peer Review Groups/Grant Study Sections:

- | | |
|------|--|
| 2009 | Medical Guidelines Consensus Board, <i>Kidney Disease Outcomes Quality Initiatives, The American Kidney Foundation.</i> |
| 2011 | Scientific Advisory Board, <i>Alexion Pharmaceuticals.</i> |
| 2012 | Grant Study Section: Clinical Trials Award, <i>American Institute of Biological Sciences (US Army Medical Research & Material Command, DOD).</i> |

- 2013 Medical Advisory Board, *American Kidney Foundation*.
- 2013-2014 Program Committee, *American Association for the Study of Liver Diseases*.
- 2014 Grant Reviewer: *PSI (Physician Services Incorporated) Foundation*.
- 2014 Grant Reviewer: *ASTS Collaborative Scientist Award*.

Journals:

Editorial Boards

- 2013-2016 *Hepatology* (2016 impact factor 11.3)
- 2019-ongoing *American Journal of Transplantation* (2020 impact factor 8.1)

Reviewer

American Journal of Transplantation
American Journal of Kidney Diseases
Clinical Journal of the American Society of Nephrology
Transplantation
Journal of the American College of Surgeons
Surgery
Hepatology
Clinical Transplantation
Transplant International
New England Journal of Medicine
Annals of Surgical Oncology
Clinics and Research in Hepatology & Gastroenterology
Journal of Medical Ethics

Professional Organizations:

- 2004-ongoing Member, American Society of Transplant Surgeons
2007-ongoing Member, Association of Academic Surgeons

- 2010-ongoing Member, Transplantation Society
- 2012-ongoing Member, American Society for the Study of Liver Diseases
- 2014-2015 UNOS (United Network for Organ Sharing) living donor committee, member, chair data subcommittee
- 2015 Member, AALSD (American Society for the Study of Liver Diseases), organizing committee
- 2019-ongoing Medical Director, New England Donor Services, Waltham, MA
- 2020-ongoing UNOS ethics committee, at-large member
- 2021-ongoing Board Member, Donate Life Connecticut

Yale University/Hospital Committees:

Medical School Committees

- 2007-2010 Member, Vascular Biology & Therapeutics Program (Yale)
- 2013-ongoing Member, Steering Committee, Human Translational Research Program
- 2015-2017 Member, Departmental Representative, Deans Faculty Advisory Council

Departmental Committees

- 2011-ongoing Member, Appointment & Promotions Committee, Department of Surgery, School of Medicine

Hospital Committees

- 2007-ongoing Chair, Medical Review Board (Kidney Transplantation), Yale-New Haven Hospital
- 2010-ongoing Chair, Quality Assessment and Performance Review Committee (Kidney Transplantation), Yale-New Haven Hospital
- 2011-2014 Member, Blood Utilization Committee, Yale-New Haven Hospital
- 2012-2013 Member, Laboratory Utilization Review Committee

Public Service/Media Presence:

- 2012 Blog Profile, American Journal of Kidney Diseases,
"1-Day Centralized Pretransplant Work-up Model"
- 2015 News Profile, WTNH News8,
"Yale-New Haven Hospital is Celebrating National Kidney Month in a Big
Way, a Chain of Kidney Donation Surgeries Pulled off Last Week"
- 2016 News Profile, Reuters and Scientific American,
"Good Match Needed for Living Donor Transplant"
- 2016 News Profile, Fox news 61, "The Real Story-Organ Donation myths"
- 2016 News Profile, Harford Currant,
"Son, Dead 17 years, Is Link That Led to Lifesaving Kidney Donation"
- 2016 News Profile, Reuters and CBC,
"Kidney Transplants with Living Donors May Not Need Match"
- 2017 News Profile, Hartford Courant,
"Yale-New Haven Hospital Puts Connection on Display in 18-Patient, 9-
Kidney Exchange"
- 2017 Video, Yale Medicine,
"Building Communities to Support Living Organ Donors"
- 2017 News Profile, NBC CT,
"Kidney Transplant Exchange Success at Yale New Haven Hospital"
- 2018 News Profile, Center for Living Organ Donors, News Channel 12
- 2018 News Profile, Middletown press,
"West Hartford man among growing number at Yale New Haven Hospital
who donate kidneys without intended recipient"
- 2019 ISCN Speaker Highlight, Carrick Institute
- 2019 Study Profile, Yale Daily News,
"Racial Disparities in access to Kidney Transplant"
- 2019 News Profile, New England Public Media,
"The Wait for a Kidney Can Be a Lot Longer if You're Not White"

Bibliography:

Peer-Reviewed Original Research:

1. O'Herrin S, **Kulkarni S**, Kenealy W, Fechner J, Sollinger HW, Scheck J and Burlingham WJ. Expression of human recombinant beta-2 microglobulin by *Aspergillus nidulans* and its activity. *Human Immunology* 1996;51:63.
2. **Kulkarni S**, Holman P, Kopelan A, van Seventer G, van Seventer J, Kranz D and Woodle ES. Programmed cell death signaling via membrane expression of a single-chain antibody transgene. *Transplantation* 2000;127;318-322.
3. **Kulkarni S**, Naureckas E and Cronin DC. Solid-organ transplant recipients treated with drotrecogin alfa (activated) for severe sepsis. *Transplantation* 2003;75(6):899-901.
4. Schaffer RL, **Kulkarni S**, Harper A, Millis JM and Cronin DC. The sickest first? Disparities with model for end-stage liver disease-based organ allocation: one region's experience. *Liver Transplantation* 2003; 9(11):1211-5.
5. **Kulkarni S** and Cronin, DC. Ethical tensions in solid organ transplantation: The price of success. *World J Gastroenterol* 2006;12(20): 3259-3264.
6. Parekh AM, Gordon EJ, Garg AX, Waterman AD, **Kulkarni S**, Parikh CR. Living donor informed consent practices vary between US and non-US centers. *Nephrol Dial Transplant* 2008;23(10):3316-3324.
7. Formica R, Asch W, Wagner K and **Kulkarni S**. HIV Disclosure in Living Donor Kidney Transplantation. *Clinical Journal of American Society of Nephrology* 2010;5(5):924-928.
8. **Kulkarni S**, Emre S, Arvelakis A, Bia M, Asch W, Formica and Isreal G. Multidetector CT Angiography in Living Donor Kidney Transplantation: Accuracy and Discrepancies in Right Venous Anatomy. *Clinical Transplantation* 2010;25(1):77-82.
9. Caldwell C, Werdiger N, Jakab S, Schilsky M, Arvelakis A, **Kulkarni S** and Emre S. Use of Model for End-Sage liver disease exception points for early liver transplantation and successful reversal of hepatic myelopathy with review of the literature. *Liver Transplantation* 2010;16(7):818-826.

10. Solomon DA, Rabidou N, **Kulkarni S**, Formica R and Fraenkel L. Accepting a donor kidney: an evaluation of patients' and transplant surgeons' priorities. *Clinical Transplantation* 2011;25(5):786-793.
11. Tobiasova Z, Lufeng Z, Tai Y, Linfeng Q, **Kulkarni S**, Lorber M, Rodrieguez F, Choi J, Tellides F, Pober J, Kawikova I and Bothwell A. PPAR agonists prevent in vivo remodeling of human artery induces by alloreactive T cells. *Circulation* 2011;124(2):196-205.
12. Fogal B, Yi T, Wang C, Rao DA, Lebastchi A, **Kulkarni S**, Tellides G, and Pober JS. Neutralizing IL-¹⁷ reduces human arterial allograft rejection by allowing emergence of CD161(+) CD4(+) regulatory T cells. *Journal of Immunology* 2011;187(12):6268-6280.
13. Yi T, Fogal B, Hao Z, Tobiasova Z, Wang C, Rao DA, Al-Lamki RS, Kirkiles-Smith NC, **Kulkarni S**, Bradley JR, Bothwell AL, Sessa WC, Tellides G, and Pober JS. Reperfusion injury intensifies the adaptive human T cell alloresponse in a human-mouse chimeric artery model. *Arteriosclero Thromb Vasc Biol* 2012;32(2):353-360.
14. Formica RN, Barrantes F, Asch WS, Bia M, Coca S, Kalyesubula R, McCloskey B, Leary T, Arvelakis A, Stint K and **Kulkarni S**. A One-Day Centralized Work-up for Kidney Transplant Recipient Candidates: A Quality Improvement Report. *American Journal of Kidney Disease* 2012;60(2):288-294.
15. Guo X, Schmitz JC, Kenney BC, Uchio EM, **Kulkarni S** and Cha C. Intermedin is overexpressed in hepatocellular carcinoma and regulates cell proliferation and survival. *Cancer Science* 2012;103(8):1474-1480.
16. Heavner M, Tichy E, Yazdi M, Formica R, **Kulkarni S**, and Emre S. Clinical outcomes associated with conversion from brand-name to generic tacrolimus in hospitalized kidney transplant recipients. *American Journal of Health-System Pharmacy* 2013;70:1507-1512.
17. Gandelman J, Yoo P and **Kulkarni S**. Retrocaval arterial bifurcation is not a contraindication to laparoscopic right donor nephrectomy. *Journal of the American College of Surgeons* 2013;217(3):406-411.
18. Davarpanah AH, Pahade JK, Cornfield D, Gita M, **Kulkarni S**, and Isreal GM. CT angiography in potential living kidney donors: 80 kVp versus 120 kVp. *AJR American Journal of Roentgenology* 2013;201(5):W753-W760.
19. Jane-Wit D, Manes TD, Yi T, Qin L, Clark P, Kirkiles-Smith NC, Abrahimi P, Devalliere J, Moeckel G, **Kulkarni S**, Tellides G, and Pober JS. Alloantibody and

- complement promote T cell-mediated cardiac allograft vasculopathy through non-canonical NK-kB signaling in endothelial cells. *Circulation* 2013;128(23):2504-2516.
20. Thiessen C, Kim YA, Formica R, Bia M and **Kulkarni S**. Written informed consent for living kidney donors: Practices and compliance with CMS and OPTN Requirements. *American Journal of Transplantation* 2013;13(10):2713-2721.
 21. Rodriguez M, Arvelakis A, Umman V, Tanjavur V, Yoo P, **Kulkarni S**, Lucyzski S, Shilsky M and Emre S. Segmental grafts in adult and pediatric liver transplantation: improving outcomes by minimizing vascular complications. *JAMA Surgery* 2014;149(1):63-70.
 22. Thiessen C, Kim YA, Yoo PS, Rodriguez-Davalos M, Mulligan D and **Kulkarni S**. Written informed consent for living liver donor evaluation: Compliance with CMS & OPTN guidelines and alibi offers. *Liver Transplantation* 2014;20(4):416-424.
 23. Viarinho S, Choi M, Jain D, Malhotra A, **Kulkarni S**, Pashankar D, Phatak U, Patel M, Bale A, Mane S, Lifton RP, Mistry PK. Individual exome analysis in diagnosis and management of pediatric liver failure of indeterminate etiology. *Journal of Hepatology* 2014;61(5):1056-1063.
 24. Thiessen C, Kim YA, Formica R, Bia M and **Kulkarni S**. Confidentiality and availability of an “alibi” for potential living kidney donors in the United States. *Journal of Medical Ethics* 2015;41(7):506-510.
 25. Thiessen C, Gordon EJ, Reese PP, **Kulkarni S**. Development of a Donor-Centered Approach to Risk Assessment: Rebalancing Non-maleficence and Autonomy. *American Journal of Transplantation* 2015;15(9):2314-2323.
 26. Guerra CM, Formica RN, **Kulkarni S**, Asch WS and Tichy EM. Duration of prophylaxis against fungal infection in kidney transplant recipients. *Progress in Transplantation* 2015;25(4):311-315.
 27. Tooley JE, Bohl DD, **Kulkarni S**, Rodriguez-Davalos MI, Mangi A, Mulligan DC, and Yoo PS. Perioperative outcomes of coronary artery bypass graft in renal transplant recipients in the United States: results from the Nationwide Inpatient Sample. *Clinical Transplantation* 2016;30(10):1258-1263
 28. Thiessen C, **Kulkarni S**, Reese PP and Gordon EJ. A call for research on individuals who opt out of living kidney donation: Challenges and opportunities. *Transplantation* 2016;100(12):2527-2532

29. **Kulkarni S**, Thiessen C, Formica R, Schilsky M, Mulligan D and D' Aquila R. The long-term follow-up and support for living organ donors: A center-based initiative founded on developing a community of living donors. *American Journal of Transplantation* 2016;16(12):3385-3391. **[Cover Citation]**
30. **Kulkarni S**, Kirkles-Smith N, Deng YH, Formica RN, Moeckel G, Broecker V, Bow L, Tomlin R and Pober J. Eculizumab for chronic antibody-mediated rejection in kidney transplant recipients randomized-controlled trial. *American Journal of Transplantation* 2017;17(13):682-691.
31. Callender GG, Malinowski J, Javid M, Zhang Y, Huang H, Quinn CE, Carling T, Tomlin R, Smith JD, and **Kulkarni S**. Parathyroidectomy prior to kidney transplant decreases graft failure. *Surgery* 2017;161(1):44-50.
32. **Kulkarni S**, Hall I, Formica R, Thiessen C, Stewart D, Gan G, Greene E, and Deng Y. Transition Probabilities Between Changing Sensitization Levels, Waitlist Activity Status, and Competing Risk Kidney Transplant Outcomes Using Multi-State Modeling. *PLoSone* 2017;12(12):e0190277.
33. Thiessen C and **Kulkarni S**. The Psychosocial Impact of Withdrawing from Living Kidney Donation. *Current Transplantation Reports* 2017;43(11):756-761.
34. Dorflinger LM, **Kulkarni S**, Thiessen C, Klarman S, and Frankel L. Assessing Living Donor Priorities through Nominal Group Technique. *Progress in Transplantation* 2018;28(1):29-35.
35. McCauley M, Mussell A, Goldberg D, Sawinski D, Molina RN, Tomlin R, Doshi SD, Abt P, Bloom R, Blumberg E, **Kulkarni S**, Esnaola G, Shults J, Thiessen C, and Reese PP. Race, Risk, and Willingness of End-stage Renal Disease Patients Without Hepatitis C (HCV) to Accept an HCV-infected Kidney Transplant. *Transplantation* 2018;102(4):e163-e170.
36. **Kulkarni S**, Ladin K, Haakinson D, Greene E, Geilang G, and Deng Y. Association of Racial Disparity with Access to Kidney Transplant After the Implementation of the New Kidney Allocation System. *JAMASurgery* 2019;154(7):618-625.
37. Schroppel B, Akalin E, Baweja M, Bloom RD, Florman S, Goldstein M, Haydel B, Hricik DE, **Kulkarni S**, Levine M, Mehrorta A, Patel A, Poggio ED, Ratner L, Shapiro R, Heeger PS. Peritransplant eculizumab does not prevent delayed graft function in deceased donor kidney transplant recipients: Results of two randomized controlled pilot trials. *American Journal of Transplantation* 2020;20(2):564-572.

38. **Kulkarni S**, Wei G, Jiang W, Lopez L, Parikh CR, Hall IE. Outcomes from right versus left deceased-donor kidney transplants: A US national cohort study. *American Journal of Kidney Diseases* 2020;70(5):725-735.
39. Thiessen C, Gannon J, Li S, Skrip L, Dobosz D, Gan G, Deng Y, Kennedy C, Gray D, Mussell A, Reese P, Gordon E, **Kulkarni S**. Quantifying Risk Tolerance Among Potential Living Kidney Donors with the Donation-Specific Risk Questionnaire. *American Journal of Kidney Diseases* 2021;87(2):246-258.
40. Marwan A, Cohen E, Ma L, Cisse'OH, Gan G, Deng YH, Belfield C, Asch W, Gant M, Gleeson S, Koff A, gaston D, Topal J, Curran S, **Kulkarni S**, Kovacs JA, Malinis M. Genetic and Epidemiologic Analyses of an Outbreak of *Pneumocystis jirovecii* Pneumonia among Kidney Transplant Recipients in the United States. *Clinical Infectious Disease* 2021, epub ahead of print.

Peer-Reviewed Reviews, Practice Guidelines, Standards, & Consensus Statements:

1. Woodle ES and **Kulkarni S**. Programmed Cell Death. *Transplantation* 1998;681-691.
2. **Kulkarni S** and Cronin DC. Ethics in Liver Transplantation. *Seminars in Liver Disease* 2006;26(3):234-238.
3. **Kulkarni S**, Malago, M and Cronin DC. Living donor liver transplantation for pediatric and adult recipients. *Nature: Clinical Gastroenterology and Hepatology*. 2006;3(3):149-157.
4. Friedman AL, Geoghean SR, Sowers NM, **Kulkarni S**, and Formica RN. Medication errors in the outpatient setting: classification and root cause analysis. *Archives of Surgery* 2007;142(3):278-283.
5. Licure A, **Kulkarni S**, Formica R, Ultrasonography and Clinical Management in the Renal Transplant Recipient. *US Nephrology* 2008 1-4.
6. Bia M, Adey BA, Bloom RD, Chan L, **Kulkarni S** and Tomlanovich S. KDOQI US Commentary on the 2009 KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients. *American Journal of Kidney Disease* 2010;56(2):189-218.
7. **Kulkarni S** and Taddei T. Should Hepatitis C patients with ESRD receive kidney transplants? *Seminars in Dialysis* 2011;24(4):438-439.
8. Yoo P and **Kulkarni S**. Anatomical considerations for the surgical resection of hepatocellular carcinoma. *J Clin Gastroenterol* 2013;47(suppl:S11-S5)

9. Contributors to the C4 Article (**Kulkarni S**, Appendix 1). Current Opinions in Organ Allocation. *American Journal of Transplantation* 2018;18(11):2625-2634.

Peer-Reviewed Educational Materials:

1. **Kulkarni S**, Kidney Transplantation: Surgical Procedure, American Society of Transplant Surgeons, Transplant Universe Module, 2010.
2. **Kulkarni S**, Kidney Transplantation: Surgical Complications, American Society of Transplant Surgeons, Transplant Universe Module, 2010.

Peer-Reviewed Case Reports & Technical Notes:

1. Tichy EM, Medwid AJ, Mills EA, Formica RN, **Kulkarni S**. Significant sirolimus and dronedarone interaction in a kidney transplant recipient. *Annals of Pharmacotherapy* 2010;44(7-8):1338-1341.
2. Cuffy M, Singh M, Formica R, Simmons E, Abu Alfa A, Carlson K, Girardi M, Cowper SE, and **Kulkarni S**. Renal transplantation for nephrogenic systemic fibrosis: a case report and review of the literature. *Nephrology Dialysis & Transplantation* 2011;26(3):1099-101.
3. Singh M, Singh G, Pandey A, Cha C and **Kulkarni S**. Laparoscopic repair of iatrogenic diaphragmatic hernia following radiofrequency ablation for hepatocellular carcinoma. *Hepatology Research* 2011;41:1132-1136.
4. Christakis PG, Cimsit B, **Kulkarni S**. Complication arising from a duplicated inferior vena cava following laparoscopic living donor nephrectomy. A case report. *Transplant Proc* 2012;44(5):1450-1452.
5. Merola J, Yoo PS, Schaub J, Smith JD, Rodrieguez-Davalos MI, Tichy E, Mulligan DC, Asch W, Formica R, Kashgarian M, and **Kulkarni S**. Belatacept and Eculizumab for treatment of calcineurin inhibitor-induced thrombotic microangiopathy after kidney transplantation: Case report. *Transplant Proc* 2016;48(9):3106-3108.
6. Cohen EA, Mulligan D, **Kulkarni S** and Tichy EM. De Novo Belatacept in a Human Immunodeficiency Virus-Positive Kidney Transplant Recipient. *American Journal of Transplantation* 2016;16(9):2753-2757.

Chapters:

1. **Kulkarni S**, Kopelan A. and Woodle ES. Tacrolimus and Kidney Transplantation. *Kidney Transplantation* 3rd Edition, William and Wilken
2. **Kulkarni S** and Cronin DC. Fulminant Liver Failure. *Principles of Critical Care* 3rd edition. McGraw-Hill.
3. Merola J, Cooper M, **Kulkarni S**. Living Kidney Donation. Living Donor Nephrectomy: Approaches, Innovations, and Outcomes. Springer Nature 2020

Invited Editorials & Commentaries:

1. Formica R and **Kulkarni S**. Being Thoughtful about Desensitization. *Clinical Journal of the American Society of Nephrology* 2017;12(11):1878-1880.
2. Batra R, Mulligan D, **Kulkarni S**, and Bhati C. Robotic Assisted Kidney Transplant, Reserved for the Deserved. *Journal of Clinical and Experimental Transplantation* 2018;3:1.
3. **Kulkarni S** and Ladin K. Ethical Principles Governing Organ Transplantation Apply to Paired Exchange Programs. *American Journal of Transplantation* 2020;20(5):1223-1224.
4. **Kulkarni S** and Ladin K. Leveling-Up versus Leveling-Down to Address Health Disparities in Transplantation. *American Journal of Transplantation* 2021;21(3):917-918.

Letters:

1. Cmunt K, Danovitch G, Delmonico F, Fynn-Thompson F, Glazier A, Grandes J, Gunderson S, Jendrisak M, Johnson HK, **Kulkarni S**, Lipkowitz G, Meyer K, Mulligan D, Nathan H, Mone T, Mortiz M, O'Connor K, Payne W, Souter M, Wood RP. Deceased Donor: Defining Drug-Related Deaths. *Clinical Transplantation* 2020;34(3):e13800.
2. Ladin K and **Kulkarni S**. Reply to "Ethical Principles Governing Organ Transplantation Apply to Paired Exchange Programs". *American Journal of Transplantation* 2020;20(6):1758-1759.
3. Orandi B and Kulkarni S. Everything Has Value Except Human Life. *Transplant International* 2021;34(8):1571-1572.

In Press: Peer-Reviewed Original Research

1. Morela J, Geliang G, Stewart D, Noreen S, Mulligan D, Batra R, Haakinson D, Deng Y, and **Kulkarni S**. Inactive Status is an Independent Predictor of Liver Transplant Waitlist Mortality and is Associated with a Transplant Centers Median Meld at Transplant. PloSone (re-submitted for minor revisions Sept 2021).